JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways

Apoptosis

Volumn 11, Issue 4, 2006, Pages 607-625

  Lauricella, M ^a   Emanuele, S ^a   D'Anneo, A ^a   Calvaruso, G ^a   Vassallo, B ^a   Carlisi, D ^a   Portanova, P ^a   Vento, R ^a   Tesoriere, G ^a,b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Policlinico   (Italy)

Author keywords

AP1; Apoptosis; Bortezomib; c Jun; Hepatoma; JNK

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BORTEZOMIB; CASPASE 3; CASPASE 8; CURCUMIN; CYTOCHROME C; FAS LIGAND; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN BID; PROTEIN BIMEL; PROTEIN C JUN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRAIN HEPG2; CELL SURVIVAL; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME RELEASE; HEPATOMA CELL; HUMAN; HUMAN CELL; LIVER CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CASPASE 8; CASPASES; CELL LINE; CELL LINE, TUMOR; FAS LIGAND PROTEIN; HEAT-SHOCK PROTEINS; HUMANS; LIVER; LIVER NEOPLASMS; MEMBRANE GLYCOPROTEINS; MITOCHONDRIA; MITOGEN-ACTIVATED PROTEIN KINASE 8; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-JUN; PYRAZINES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1; TUMOR NECROSIS FACTORS;

EID: 33646388007     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-006-4689-y     Document Type: Article

References (65)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-421.
2. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360.
3. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004; 15: 2009-2015.
4. Wang QE, Wani MA, Chen J, et al. Cellular ubiquitination and proteasomal functions positively modulate mammalian nucleotide excision repair. Mol Carcinog 2005; 16: 53-64.
5. Lauricella M, D'Anneo A, Giuliano M, et al. Induction of apoptosis in human osteosarcoma Saos-2 cells by the proteasome inhibitor MG132 and the protective effect of pRb. Cell Death Differ 2003; 10: 930-932.
6. Giuliano M, Lauricella M, Calvaruso G, et al. The apoptotic effects and synergistic interaction of sodium butyrate and MG132 in human retinoblastoma Y79 cells. Cancer Res 1999; 59: 5586-5595.
7. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004; 22: 304-311.
8. Orlowski RZ. Bortezomib and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 2004; 4: 171-179.
9. Chauhan D, Li G, Podar K, et al. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood 2004; 15: 2458-2466.
10. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-14379.
11. Pei XY, Dai Y, Grant S. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia 2003; 17: 2036-2045.
12. Dai Y, Rahmani M, Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 2003; 22: 7108-7122.
13. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004; 64: 5036-5043.
14. Bunn PA Jr. The potential role of proteasome inhibitors in the treatment of lung cancer. Clin Cancer Res 2004; 10: 4263-4265.
15. Yu J, Tiwari S, Steiner P, Zhang L. Differential apoptotic response to the proteasome inhibitor Bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol Ther 2003; 2: 694-699.
16. Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004; 3: 279-290.
17. Dai Y, Rahmani M, Pei XY, et al. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and- independent mechanisms. Blood 2004; 104: 509-518.
18. Cortes J, Thomas D, Koller C, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371-3376.
19. Papandreou CN, Daliani DD, Nix D, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 1: 2108-2121.
20. Kondagunta GV, Drucker B, Schwartz L, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 15: 3720-3725.
21. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. Cancer Cell 2004; 5: 215-219.
22. Emanuele S, Calvaruso G, Lauricella, et al. Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of.Bcl-XS and activation of caspase-3. Int J Oncol 2002; 21: 857-865.
23. Hansen MB, Nielsen SE, Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 1989; 119: 203-210.
24. Bojarski C, Bitter AH, Bendfeldt K, et al. Permeability of human HT-29/B6 colonic epithelium as a function of apoptosis. J Physiol 2001; 535: 541-552.
25. Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795-808.
26. Lauricella M, Calvaruso G, Carabillo M, et al. pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase. FEBS Lett 2001; 499: 191-197.
27. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
28. Emanuele S, D'Anneo A, Bellavia G, et al. Sodium butyrate induces apoptosis in human hepatoma cells by a mitochondria/caspase pathway, associated with degradation of beta-catenin, pRb and Bcl-XL. Eur J Cancer 2004; 40: 1441-1452.
29. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989; 17: 6419.
30. Ling Y-H, Liebes L, Jiang J-D, Holland JF, et al. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 2003; 9: 1145-1154.
31. Xiao D, Johnson CS, Trump DL, Singh SV. Proteasome-mediated degradation of cell division cycle 25C and cyclin-dependent kinase 1 in phenethyl isothiocyanate-induced G2-M-phase cell cycle arrest in PC-3 human prostate cancer cells. Mol Cancer Ther 2004; 3: 567-575.
32. Huang T-S, Lee S-C, Lin J-K. Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion m mouse fibroblast cells. Proc Natl Acad Sci 1991; 88: 5292-5296.
33. Hartl M, Bader AG, Bister K. Molecular targets of the oncogenic transcription factor jun. Curr Cancer Drug Targets 2003; 3: 41-55.
34. Lin A, Dibling B. The true face of JNK activation in apoptosis. Aging Cell 2002; 1: 112-116.
35. Freeman SM, Whartenby KA. The role of the mitogen-activated protein kinase cellular signaling pathway in tumor cell survival and apoptosis. Drug News Perspect 2004; 17: 237-242.
36. Zhang Y, Chen F. Reactive oxygen species (ROS), trouble-makers between nuclear factor-kappaB (NF-kappaB) and c-Jun NH(2)-terminal kinase (JNK). Cancer Res 2004; 64: 1902-1905.
37. Mosser DD, Morimoto RI. Molecular chaperones and the stress of oncogenesis. Oncogene 2004; 23: 2907-2918.
38. Merienne K, Helmlinger D, Perkin GR, Devys D, Trottier Y. Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway. J Biol Chem 2003; 278: 16957-16967.
39. Wang JH, Yao MZ, Zhang ZL, Zhang YH, Wang YG, Liu XY. HSF1 blockade-induced tumor thermotolerance abolishment is mediated by JNK-dependent caspase-3 activation. Biochem Biophys Res Commun 2004; 321: 736-745.
40. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004; 16: 139-144.
41. Wang S, El-Deiry WS. The p53 pathway: targets for the development of novel cancer therapeutics. Cancer Treat Res 2004; 119: 175-187.
42. Weiss RH. p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell 2003; 4: 425-429.
43. Fotouhi N, Graves B. Small molecule inhibitors of p53/MDM2 interaction. Curr Top Med Chem 2005; 5: 159-165.
44. Liu FT, Goff LK, Hao JH, et al. Increase in the ratio of mitochondrial Bax/Bcl-XL induces Bax activation in human leukemic K562 cell line. Apoptosis 2004; 9: 377-384.
45. Puthalakath H, Strasser A. Keeping killers on a tight leash: Transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 2002; 9: 505-512.
46. Tan TT, Degenhardt K, Nelson DA, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005; 7: 227-238.
47. Tong X, Lin S, Fujii M, et al. Molecular mechanisms of echinocystic acid-induced apoptosis in HepG2 cells. Biochem Biophys Res Commun 2004; 321: 539-546.
48. Dong Z, Zhou L, Del Villar K, et al. JIP1 regulates neuronal apoptosis in response to stress. Mol Brain Res 2005; 134: 282-293.
49. Tsuboi H, Hossain K, Akhand AA, et al. Paeoniflorin induces apoptosis of lymphocytes through a redox-linked mechanism. J Cell Biochem 2004; 93: 162-72.
50. Jian YT, Mai GF, Wang JD, et al. Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 2005; 11: 1747-52.
51. Eferl R, Wagner EF. AP-1: A double-edged sword in tumorigenesis. Nat Rev Canc 2003; 3: 859-868.
52. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol 2002; 4: 131-136.
53. Pyrzynska B, Mosieniak G, Kaminska B. Changes of the trans-activating potential of AP-1 transcription factor during cyclosporin A-induced apoptosis of glioma cells are mediated by phosphorylation and alterations of AP-1 composition. J Neurochem 2000; 74: 42-51.
54. Hahm ER, Gho YS, Park S, et al. Synthetic curcumin analogs inhibit activator protein-1 transcription and tumor-induced angiogenesis. Biochem Biophys Res Commun 2004; 321: 337-344.
55. Kang G, Kong PJ, Yuh YJ, et al. Curcumin suppresses lipopolysaccharide- induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappab bindings in BV2 microglial cells. J Pharmacol Sci 2004; 94: 325-328.
56. Kaminska B, Pyrzynska B, Ciechomska I, et al. Modulation of the composition of AP-1 complex and its impact on transcriptional activity. Acta Neurobiol Exp 2000; 60: 395-402.
57. Li L, Feng Z, Porter AG. JNK-dependent phosphorylation of c-Jun on serine 63 mediates nitric oxide-induced apoptosis of neuroblastoma cells. J Biol Chem 2004; 279: 4058-4065.
58. Yin KJ, Lee JM, Chen SD, et al. Amyloid-beta induces Smac release via AP-1/Bim activation in cerebral endothelial cells. J Neurosci 2002; 22: 9764-9770.
59. Eichhorst ST, Muller M, Li-Weber M, et al. A novel AP-1 element in the CD95 ligand promoter is required for induction of apoptosis in hepatocellular carcinoma cells upon treatment with anticancer drugs. Mol Cell Biol 2000; 20: 7826-7837.
60. Hosokawa N, Takechi H, Yokota S, et al. Structure of the gene encoding the mouse 47-kDa heat-shock protein (HSP47). Gene 1993; 126: 187-193.
61. Houston A, O'Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol 2004; 4: 321-326.
62. Gomez-Bougie P, Bataille R, Amiot M. Endogenous association of Bim BH3-only protein with Mcl-1, Bcl-xL and Bcl-2 on mitochondria in human B cells. Eur J Immunol 2005; 35: 971-976.
63. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 7: 525-535.
64. Wu Y, Mehew JW, Heckman CA, et al. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001; 20: 240-251.
65. Zamzami N, El Hamel C, Maisse C, et al. Bid acts on the permeability transition pore complex to induce apoptosis. Oncogene 2000; 19: 6342-6350.